 Zalutumumab

Zalutumumab (proposed trade name HuMax-EGFR) is a fully human IgG1 monoclonal antibody (mAb) directed towards the epidermal growth factor receptor (EGFR).It is a product developed by Genmab in Utrecht, the Netherlands.